PCI BIOTECH HOLDING ASA (PCIB.OL) Stock Price, Forecast & Analysis
OSL:PCIB • NO0010405640
PCIB.OL Key Statistics, Chart & Performance
The current stock price of PCIB.OL is 0.216 NOK. In the past month the price decreased by -16.92%. In the past year, price decreased by -83.76%.
PCIB.OL Technical Analysis
PCIB.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PCIB.OL. PCIB.OL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PCIB.OL Financial Highlights
Over the last trailing twelve months PCIB.OL reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 19.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.63% | ||
| ROE | -131.18% | ||
| Debt/Equity | 0 |
PCIB.OL Forecast & Estimates
PCIB.OL Ownership
PCIB.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.02 | 43.529B | ||
| ARGX | ARGENX SE | 28.07 | 43.504B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.617B | ||
| ABVX | ABIVAX SA | N/A | 8.158B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.868B | ||
| GLPG | GALAPAGOS NV | N/A | 1.866B | ||
| 6IV | INVENTIVA SA | N/A | 1.034B | ||
| IVA | INVENTIVA SA | N/A | 1.008B | ||
| NANO | NANOBIOTIX | N/A | 994.371M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PCIB.OL
Company Profile
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Company Info
PCI BIOTECH HOLDING ASA
Ullernchauseen 64
Oslo OSLO NO
Employees: 5
Phone: 4767115400
PCI BIOTECH HOLDING ASA / PCIB.OL FAQ
What does PCIB do?
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
What is the stock price of PCI BIOTECH HOLDING ASA today?
The current stock price of PCIB.OL is 0.216 NOK. The price decreased by -5.68% in the last trading session.
Does PCIB stock pay dividends?
PCIB.OL does not pay a dividend.
What is the ChartMill rating of PCI BIOTECH HOLDING ASA stock?
PCIB.OL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists PCIB stock?
PCIB.OL stock is listed on the Euronext Oslo exchange.
What is the GICS sector and industry of PCIB stock?
PCI BIOTECH HOLDING ASA (PCIB.OL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PCI BIOTECH HOLDING ASA?
PCI BIOTECH HOLDING ASA (PCIB.OL) has a market capitalization of 8.06M NOK. This makes PCIB.OL a Nano Cap stock.